$UNCY
Unicycive Therapeutics, Inc.

2024 Q4 Form 10-Q Financial Statement

#000121390024097118 Filed on November 13, 2024

View on sec.gov

Income Statement

Concept 2024 Q4 2024 Q3
Revenue
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.206M
YoY Change 569.31%
% of Gross Profit
Research & Development $3.045M
YoY Change -9.7%
% of Gross Profit
Depreciation & Amortization $6.000K
YoY Change -40.0%
% of Gross Profit
Operating Expenses $6.251M
YoY Change 5.27%
Operating Profit -$6.251M
YoY Change 5.27%
Interest Expense $401.0K
YoY Change 2127.78%
% of Operating Profit
Other Income/Expense, Net $2.155M
YoY Change 53.93%
Pretax Income -$4.096M
YoY Change -5.4%
Income Tax
% Of Pretax Income
Net Earnings -$4.096M
YoY Change -5.47%
Net Earnings / Revenue
Basic Earnings Per Share -$0.05
Diluted Earnings Per Share -$0.05
COMMON SHARES
Basic Shares Outstanding 103.8M shares 94.36M shares
Diluted Shares Outstanding 88.94M shares

Balance Sheet

Concept 2024 Q4 2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $32.35M
YoY Change 125.41%
Cash & Equivalents $32.35M
Short-Term Investments
Other Short-Term Assets $5.394M
YoY Change 27.82%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $37.74M
YoY Change 103.25%
LONG-TERM ASSETS
Property, Plant & Equipment $61.00K
YoY Change 117.86%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $833.0K
YoY Change -4.58%
TOTAL ASSETS
Total Short-Term Assets $37.74M
Total Long-Term Assets $833.0K
Total Assets $38.57M
YoY Change 98.41%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $548.0K
YoY Change -49.45%
Accrued Expenses $2.992M
YoY Change 18.26%
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $10.46M
YoY Change -32.33%
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change
Other Long-Term Liabilities $265.0K
YoY Change -51.82%
Total Long-Term Liabilities $265.0K
YoY Change -51.82%
TOTAL LIABILITIES
Total Short-Term Liabilities $10.46M
Total Long-Term Liabilities $265.0K
Total Liabilities $10.72M
YoY Change -33.01%
SHAREHOLDERS EQUITY
Retained Earnings -$79.70M
YoY Change 40.56%
Common Stock $98.00K
YoY Change 180.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $27.85M
YoY Change
Total Liabilities & Shareholders Equity $38.57M
YoY Change 98.41%

Cashflow Statement

Concept 2024 Q4 2024 Q3
OPERATING ACTIVITIES
Net Income -$4.096M
YoY Change -5.47%
Depreciation, Depletion And Amortization $6.000K
YoY Change -40.0%
Cash From Operating Activities -$9.252M
YoY Change 109.32%
INVESTING ACTIVITIES
Capital Expenditures $24.00K
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$24.00K
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -157.0K
YoY Change 214.0%
NET CHANGE
Cash From Operating Activities -9.252M
Cash From Investing Activities -24.00K
Cash From Financing Activities -157.0K
Net Change In Cash -9.433M
YoY Change 111.03%
FREE CASH FLOW
Cash From Operating Activities -$9.252M
Capital Expenditures $24.00K
Free Cash Flow -$9.276M
YoY Change 109.86%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
us-gaap Revenues
Revenues
usd
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-40582
dei Entity Registrant Name
EntityRegistrantName
UNICYCIVE THERAPEUTICS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
81-3638692
dei Entity Address Address Line1
EntityAddressAddressLine1
4300 El Camino Real
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 210
dei Entity Address City Or Town
EntityAddressCityOrTown
Los Altos
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94022
dei City Area Code
CityAreaCode
(650)
dei Local Phone Number
LocalPhoneNumber
351-4495
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
dei Trading Symbol
TradingSymbol
UNCY
dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2024Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
103796406 shares
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
9701000 usd
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
32347000 usd
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3698000 usd
CY2024Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5394000 usd
CY2023Q4 us-gaap Assets Current
AssetsCurrent
13399000 usd
CY2024Q3 us-gaap Assets Current
AssetsCurrent
37741000 usd
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
766000 usd
CY2024Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
772000 usd
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
26000 usd
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
61000 usd
CY2023Q4 us-gaap Assets
Assets
14191000 usd
CY2024Q3 us-gaap Assets
Assets
38574000 usd
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
839000 usd
CY2024Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
548000 usd
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3234000 usd
CY2024Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2992000 usd
CY2023Q4 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
13134000 usd
CY2024Q3 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
6377000 usd
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
327000 usd
CY2024Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
542000 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
17534000 usd
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
10459000 usd
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
466000 usd
CY2024Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
265000 usd
CY2023Q4 us-gaap Liabilities
Liabilities
18000000 usd
CY2024Q3 us-gaap Liabilities
Liabilities
10724000 usd
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
400000000 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
34756049 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
34756049 shares
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
97858406 shares
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
97858406 shares
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
35000 usd
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
98000 usd
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
60697000 usd
CY2024Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
107497000 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-64541000 usd
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-79745000 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-3809000 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
27850000 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
14191000 usd
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
38574000 usd
us-gaap Revenues
Revenues
675000 usd
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3372000 usd
CY2024Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3045000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8669000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
14726000 usd
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2566000 usd
CY2024Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3206000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6467000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8130000 usd
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
5938000 usd
CY2024Q3 us-gaap Operating Expenses
OperatingExpenses
6251000 usd
us-gaap Operating Expenses
OperatingExpenses
15136000 usd
us-gaap Operating Expenses
OperatingExpenses
22856000 usd
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-5938000 usd
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-6251000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-14461000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-22856000 usd
CY2023Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
227000 usd
CY2024Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
416000 usd
us-gaap Investment Income Interest
InvestmentIncomeInterest
475000 usd
us-gaap Investment Income Interest
InvestmentIncomeInterest
947000 usd
CY2023Q3 us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
18000 usd
CY2024Q3 us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
15000 usd
us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
63000 usd
us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
51000 usd
CY2023Q3 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-1396000 usd
CY2024Q3 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-1754000 usd
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
8697000 usd
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-6756000 usd
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1605000 usd
CY2024Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2155000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-8285000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
7652000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-4333000 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-4096000 usd
us-gaap Net Income Loss
NetIncomeLoss
-22746000 usd
us-gaap Net Income Loss
NetIncomeLoss
-15204000 usd
CY2023Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-4405000 usd
CY2024Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-4096000 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-23613000 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-16299000 usd
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.13
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.13
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.05
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.05
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.12
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.12
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.3
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.3
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
32633074 shares
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
32633074 shares
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
88943212 shares
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
88943212 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
21100206 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
21100206 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
54073701 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
54073701 shares
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-466000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-14575000 usd
CY2023Q1 uncy Deemed Dividends On Series A1 Preferred Stock
DeemedDividendsOnSeriesA1PreferredStock
-192000 usd
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
7000 usd
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
144000 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-15082000 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-3838000 usd
CY2023Q2 uncy Deemed Dividends On Series A1 Preferred Stock
DeemedDividendsOnSeriesA1PreferredStock
-603000 usd
CY2023Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
7000 usd
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
144000 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-19372000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-4333000 usd
CY2023Q3 uncy Deemed Dividends On Series A1 Preferred Stock
DeemedDividendsOnSeriesA1PreferredStock
-72000 usd
CY2023Q3 uncy Stock Issued During Period Value Issuance Of Series A2 Preferred Stock And Common Stock Upon Conversion Of Series A1 Preferr
StockIssuedDuringPeriodValueIssuanceOfSeriesA2PreferredStockAndCommonStockUponConversionOfSeriesA1Preferr
26275000 usd
CY2023Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
7000 usd
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
929000 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
3434000 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-3809000 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-20963000 usd
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Other
AdjustmentsToAdditionalPaidInCapitalOther
208000 usd
CY2024Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
2000 usd
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
522000 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
-24456000 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
9855000 usd
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Other
AdjustmentsToAdditionalPaidInCapitalOther
887000 usd
CY2024Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1000 usd
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
641000 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
-14846000 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-4096000 usd
CY2024Q3 uncy Stock Issued During Period Value Issuance Of Series B2 Preferred Stock And Common Stock Upon Conversion Of Series B1 Preferr
StockIssuedDuringPeriodValueIssuanceOfSeriesB2PreferredStockAndCommonStockUponConversionOfSeriesB1Preferr
46187000 usd
CY2024Q3 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
605000 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
27850000 usd
us-gaap Net Income Loss
NetIncomeLoss
-22746000 usd
us-gaap Net Income Loss
NetIncomeLoss
-15204000 usd
us-gaap Depreciation
Depreciation
6000 usd
us-gaap Depreciation
Depreciation
15000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
1217000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
1768000 usd
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
8697000 usd
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-6756000 usd
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
196000 usd
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
279000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1884000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1677000 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
849000 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-181000 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-179000 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-271000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-13844000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-22027000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
12000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
50000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-12000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-50000 usd
uncy Payments On Financed Insurance Policies
PaymentsOnFinancedInsurancePolicies
291000 usd
uncy Payments On Financed Insurance Policies
PaymentsOnFinancedInsurancePolicies
368000 usd
uncy Proceed From Issuance Of Preferred Stock
ProceedFromIssuanceOfPreferredStock
-3813000 usd
us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
50000000 usd
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
2153000 usd
us-gaap Proceeds From Issuance Of Preferred Stock Preference Stock And Warrants
ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants
30190000 usd
us-gaap Payments Of Dividends Preferred Stock And Preference Stock
PaymentsOfDividendsPreferredStockAndPreferenceStock
1095000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
27746000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
44723000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
13890000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
22646000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
455000 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
9701000 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
14345000 usd
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
32347000 usd
us-gaap Stock Issued1
StockIssued1
867000 usd
uncy Fair Value Of Warrants Issued In Connection With The Issuance Of Preferred Stock
FairValueOfWarrantsIssuedInConnectionWithTheIssuanceOfPreferredStock
2831000 usd
uncy Issuance Of Series A2 Preferred Stock And Common Stock Upon Conversion Of Series A1 Preferr
IssuanceOfSeriesA2PreferredStockAndCommonStockUponConversionOfSeriesA1Preferr
26274000 usd
uncy Issuance Of Series B2 Preferred Stock And Common Stock Upon Conversion Of Series B1 Preferr
IssuanceOfSeriesB2PreferredStockAndCommonStockUponConversionOfSeriesB1Preferr
46187000 usd
uncy Deferred Insurance Charges Included In Prepaid Expenses And Other Current Assets
DeferredInsuranceChargesIncludedInPrepaidExpensesAndOtherCurrentAssets
397000 usd
uncy Deferred Preclinical Charges Included In Prepaid Expenses And Other Current Assets
DeferredPreclinicalChargesIncludedInPrepaidExpensesAndOtherCurrentAssets
293000 usd
uncy Deferred Preclinical Charges Included In Prepaid Expenses And Other Current Assets
DeferredPreclinicalChargesIncludedInPrepaidExpensesAndOtherCurrentAssets
19000 usd
us-gaap Interest Paid Net
InterestPaidNet
51000 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-64500000 usd
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-79700000 usd
CY2024Q1 us-gaap Proceeds From Sale Of Other Receivables
ProceedsFromSaleOfOtherReceivables
46200000 usd
us-gaap Use Of Estimates
UseOfEstimates
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Use of Estimates</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of financial statements in conformity with GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the periods presented. Management believes that these estimates and assumptions are reasonable; however, actual results may differ and could have a material effect on future results of operations and financial position. Significant items subject to such estimates and assumptions include revenues, stock-based compensation, research contract progress estimates, and the fair value of warrant liabilities. Actual results may materially differ from those estimates.</p>
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1 pure
CY2024Q3 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
6377000 usd
CY2024Q3 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
6377000 usd
CY2023Q4 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
13134000 usd
CY2023Q4 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
13134000 usd
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Concentration of Credit Risk</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Financial instruments that potentially subject the Company to concentration of credit risk consist of cash and cash equivalents. The cash and cash equivalents the Company uses to satisfy working capital and operating expense needs are held in accounts at various financial institutions. Cash balances may at times exceed federally insured limits. Cash and cash equivalents could be adversely impacted, including the loss of uninsured deposits and other uninsured financial assets, if one or more of the financial institutions in which the Company holds its cash or cash equivalents fails or is subject to other adverse conditions in the financial or credit markets. No such losses have been incurred through September 30, 2024.</p>
us-gaap Effective Income Tax Rate Reconciliation Other Reconciling Items Percent
EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
0.50 pure
CY2017Q4 uncy Second Clinical Trial Payment
SecondClinicalTrialPayment
50000 usd
CY2017Q4 uncy Agreement Due Payments
AgreementDuePayments
1650000 usd
CY2017Q4 uncy Royalty Pecentage
RoyaltyPecentage
0.02 pure
CY2021Q3 us-gaap Capitalization Longterm Debt And Equity
CapitalizationLongtermDebtAndEquity
50000000 usd
us-gaap Other Research And Development Expense
OtherResearchAndDevelopmentExpense
2200000 usd
uncy Sublicense Income Percentage
SublicenseIncomePercentage
0.40 pure
CY2023Q4 us-gaap Accounts Payable And Accrued Liabilities Current And Noncurrent
AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent
2000000 usd
CY2022Q1 uncy Revisions Reduced The Overall Budget
RevisionsReducedTheOverallBudget
2900000 usd
CY2023Q1 us-gaap Costs And Expenses Related Party
CostsAndExpensesRelatedParty
100000 usd
CY2023Q2 us-gaap Costs And Expenses Related Party
CostsAndExpensesRelatedParty
2900000 usd
CY2023Q1 uncy Milestone Payments
MilestonePayments
3700000 usd
uncy Payment Amount
PaymentAmount
3700000 usd
uncy Upfront Fees
UpfrontFees
675000 usd
uncy Transaction Price
TransactionPrice
675000 usd
us-gaap Proceeds From License Fees Received
ProceedsFromLicenseFeesReceived
675000 usd
CY2023Q4 us-gaap Prepaid Insurance
PrepaidInsurance
270000 usd
CY2024Q3 us-gaap Prepaid Insurance
PrepaidInsurance
397000 usd
CY2023Q4 uncy Prepaid Preclinical Services Current
PrepaidPreclinicalServicesCurrent
3103000 usd
CY2024Q3 uncy Prepaid Preclinical Services Current
PrepaidPreclinicalServicesCurrent
4310000 usd
CY2023Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
325000 usd
CY2024Q3 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
687000 usd
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3698000 usd
CY2024Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5394000 usd
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
42000 usd
CY2024Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
92000 usd
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
16000 usd
CY2024Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
31000 usd
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
26000 usd
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
61000 usd
CY2023Q4 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
821000 usd
CY2024Q3 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
519000 usd
CY2023Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
18000 usd
CY2024Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
29000 usd
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
839000 usd
CY2024Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
548000 usd
CY2023Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
1917000 usd
CY2024Q3 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
1402000 usd
CY2023Q4 uncy Accrued Drug Development Costs Current
AccruedDrugDevelopmentCostsCurrent
1034000 usd
CY2024Q3 uncy Accrued Drug Development Costs Current
AccruedDrugDevelopmentCostsCurrent
1068000 usd
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
283000 usd
CY2024Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
522000 usd
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3234000 usd
CY2024Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2992000 usd
CY2021Q4 us-gaap Area Of Land
AreaOfLand
2367 sqft
CY2024Q3 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P2Y
CY2023Q1 us-gaap Area Of Land
AreaOfLand
2456 sqft
us-gaap Lessee Operating Lease Option To Extend
LesseeOperatingLeaseOptionToExtend
three additional years
CY2023Q1 us-gaap Lessee Operating Lease Discount Rate
LesseeOperatingLeaseDiscountRate
0.10 pure
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
144000 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
608000 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
118000 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
871000 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
64000 usd
CY2024Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
807000 usd
CY2024Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
542000 usd
CY2024Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
265000 usd
CY2023Q1 us-gaap Repayments Of Debt
RepaymentsOfDebt
210000 usd
CY2021Q4 us-gaap Defined Contribution Plan Employer Matching Contribution Percent
DefinedContributionPlanEmployerMatchingContributionPercent
1 pure
CY2023 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
107000 usd
us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
104000 usd
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
400000000 shares
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q3 us-gaap Share Price
SharePrice
5
us-gaap Conversion Of Stock Shares Converted1
ConversionOfStockSharesConverted1
736773 shares
us-gaap Conversion Of Stock Shares Issued1
ConversionOfStockSharesIssued1
184193 shares
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
4784193 shares
CY2023Q4 uncy Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePrice
6
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Terms
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
P2Y6M14D
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
4784193 shares
CY2024Q3 uncy Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePrice
6
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Terms
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
P1Y9M14D
us-gaap Stock And Warrants Issued During Period Value Preferred Stock And Warrants
StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants
2800000 usd
CY2023Q3 us-gaap Conversion Of Stock Shares Converted1
ConversionOfStockSharesConverted1
43649 shares
CY2024Q3 uncy Original Price Per Share
OriginalPricePerShare
1000
us-gaap Common Stock Voting Rights
CommonStockVotingRights
one
us-gaap Common Stock Dividends Shares
CommonStockDividendsShares
1000 shares
CY2024Q3 us-gaap Preferred Stock Liquidation Preference Value
PreferredStockLiquidationPreferenceValue
1000 usd
us-gaap Preferred Stock Dividend Rate Percentage
PreferredStockDividendRatePercentage
0.08 pure
us-gaap Common Stock Voting Rights
CommonStockVotingRights
one
us-gaap Preferred Stock Voting Rights
PreferredStockVotingRights
one
CY2024Q3 us-gaap Preferred Stock Convertible Shares Issuable
PreferredStockConvertibleSharesIssuable
1000000 shares
CY2024Q3 us-gaap Preferred Stock Convertible Conversion Price
PreferredStockConvertibleConversionPrice
1
CY2023Q1 us-gaap Adjustment Of Warrants Granted For Services
AdjustmentOfWarrantsGrantedForServices
2800000 usd
CY2023 us-gaap Adjustment Of Warrants Granted For Services
AdjustmentOfWarrantsGrantedForServices
13100000 usd
us-gaap Adjustment Of Warrants Granted For Services
AdjustmentOfWarrantsGrantedForServices
6400000 usd
CY2023Q2 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
1302326 shares
CY2023Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Number Of Shares Period Increase Decrease
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfSharesPeriodIncreaseDecrease
12775996 shares
CY2024Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Number Of Shares Period Increase Decrease
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfSharesPeriodIncreaseDecrease
20775996 shares
CY2023Q4 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
2815503 shares
CY2024Q3 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
7433327 shares
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
10302086 shares
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
1
CY2023Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P9Y4M2D
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
1196000 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
3370411 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
1
uncy Sharebased Compensation Arrangement By Sharebased Payment Award Option Outstanding Weighted Average Remaining Contractual Termin Years Options Granted
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionOutstandingWeightedAverageRemainingContractualTerminYearsOptionsGranted
P9Y7M6D
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
1357 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
3.27
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
13671140 shares
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
1
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y10M2D
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
81000 usd
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
4675005 shares
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
1.28
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P8Y3M21D
CY2024Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
39000 usd
CY2021 uncy Exercised Stock Option
ExercisedStockOption
383721 shares
CY2021 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
119000 usd
CY2024Q3 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
0 shares
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
2500 usd
CY2022Q2 us-gaap Stock Issued During Period Shares Restricted Stock Award Gross
StockIssuedDuringPeriodSharesRestrictedStockAwardGross
10000 shares
CY2022Q2 us-gaap Restricted Investments At Fair Value
RestrictedInvestmentsAtFairValue
7200 usd
CY2022Q2 us-gaap Option Contract Indexed To Equity Settlement Share Fair Value Per Share
OptionContractIndexedToEquitySettlementShareFairValuePerShare
0.72
CY2023Q3 us-gaap Stock Issued During Period Shares Restricted Stock Award Gross
StockIssuedDuringPeriodSharesRestrictedStockAwardGross
10000 shares
CY2023Q3 us-gaap Restricted Investments At Fair Value
RestrictedInvestmentsAtFairValue
7500 usd
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
0.75
CY2024Q3 us-gaap Stock Issued During Period Shares Restricted Stock Award Gross
StockIssuedDuringPeriodSharesRestrictedStockAwardGross
11765 shares
CY2024Q3 us-gaap Restricted Investments At Fair Value
RestrictedInvestmentsAtFairValue
4000 usd
CY2024Q3 us-gaap Option Contract Indexed To Equity Settlement Share Fair Value Per Share
OptionContractIndexedToEquitySettlementShareFairValuePerShare
0.34
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
929000 usd
CY2024Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
605000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1217000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1768000 usd
uncy Annual Net Cash Flow From Operations Percentage
AnnualNetCashFlowFromOperationsPercentage
0.75 pure
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y11M1D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y3M
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-4333000 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-4096000 usd
us-gaap Net Income Loss
NetIncomeLoss
-22746000 usd
us-gaap Net Income Loss
NetIncomeLoss
-15204000 usd
CY2023Q3 us-gaap Dividends Preferred Stock Cash
DividendsPreferredStockCash
72000 usd
us-gaap Dividends Preferred Stock Cash
DividendsPreferredStockCash
867000 usd
uncy Cash Dividends Preferred Stock
CashDividendsPreferredStock
-1095000 usd
CY2023Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-4405000 usd
CY2023Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-4405000 usd
CY2024Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-4096000 usd
CY2024Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-4096000 usd
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-23613000 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-23613000 usd
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-16299000 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-16299000 usd
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
32633074 shares
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
32633074 shares
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
88943212 shares
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
88943212 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
21100206 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
21100206 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
54073701 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
54073701 shares
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.13
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.13
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.05
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.05
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.12
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.12
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.3
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.3
CY2023Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
176063976 shares
CY2024Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
209993175 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
176063976 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
209993175 shares
CY2024Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q3 us-gaap Revenues
Revenues
usd
CY2024Q3 us-gaap Revenues
Revenues
usd
CY2023Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
usd
CY2024Q1 uncy Stock Issued During Period Value Issuance Of Series B1 Preferred Stock Net Of Issuance Costs
StockIssuedDuringPeriodValueIssuanceOfSeriesB1PreferredStockNetOfIssuanceCosts
usd
CY2024Q1 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
usd
CY2024Q1 us-gaap Stock Issued During Period Value Conversion Of Units
StockIssuedDuringPeriodValueConversionOfUnits
usd
CY2024Q2 us-gaap Stock Issued During Period Value Conversion Of Units
StockIssuedDuringPeriodValueConversionOfUnits
usd
CY2024Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
usd
uncy Proceed From Issuance Of Preferred Stock
ProceedFromIssuanceOfPreferredStock
usd
us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
usd
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
usd
us-gaap Proceeds From Issuance Of Preferred Stock Preference Stock And Warrants
ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants
usd
us-gaap Payments Of Dividends Preferred Stock And Preference Stock
PaymentsOfDividendsPreferredStockAndPreferenceStock
usd
us-gaap Stock Issued1
StockIssued1
usd
uncy Fair Value Of Warrants Issued In Connection With The Issuance Of Preferred Stock
FairValueOfWarrantsIssuedInConnectionWithTheIssuanceOfPreferredStock
usd
uncy Issuance Of Series A2 Preferred Stock And Common Stock Upon Conversion Of Series A1 Preferr
IssuanceOfSeriesA2PreferredStockAndCommonStockUponConversionOfSeriesA1Preferr
usd
uncy Issuance Of Series B2 Preferred Stock And Common Stock Upon Conversion Of Series B1 Preferr
IssuanceOfSeriesB2PreferredStockAndCommonStockUponConversionOfSeriesB1Preferr
usd
uncy Deferred Insurance Charges Included In Prepaid Expenses And Other Current Assets
DeferredInsuranceChargesIncludedInPrepaidExpensesAndOtherCurrentAssets
usd
us-gaap Interest Paid Net
InterestPaidNet
usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
usd
CY2023Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Outstanding
SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
shares
uncy Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Granted Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedWeightedAverageExercisePrice
uncy Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Warrants Granted
SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueWarrantsGranted
usd
uncy Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Exercised In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod
shares
uncy Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Exercised Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageExercisePrice
uncy Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Warrants Exercised
SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueWarrantsExercised
usd
CY2024Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Outstanding
SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
uncy Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Termin Years Options Forfeited
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerminYearsOptionsForfeited
uncy Share Based Compensation Arrangement By Share Based Payment Award Options Aggregate Intrinsic Value Options Forfeited
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueOptionsForfeited
usd
uncy Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
pure
CY2024Q3 us-gaap Dividends Preferred Stock Cash
DividendsPreferredStockCash
usd
us-gaap Dividends Preferred Stock Cash
DividendsPreferredStockCash
usd
CY2023Q3 uncy Cash Dividends Preferred Stock
CashDividendsPreferredStock
usd
CY2024Q3 uncy Cash Dividends Preferred Stock
CashDividendsPreferredStock
usd
uncy Cash Dividends Preferred Stock
CashDividendsPreferredStock
usd
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Central Index Key
EntityCentralIndexKey
0001766140

Files In Submission

Name View Source Status
0001213900-24-097118-index-headers.html Edgar Link pending
0001213900-24-097118-index.html Edgar Link pending
0001213900-24-097118.txt Edgar Link pending
0001213900-24-097118-xbrl.zip Edgar Link pending
ea0220114-10q_unicycive.htm Edgar Link pending
ea022011401ex3-1_unicycive.htm Edgar Link pending
ea022011401ex31-1_unicycive.htm Edgar Link pending
ea022011401ex31-2_unicycive.htm Edgar Link pending
ea022011401ex32-1_unicycive.htm Edgar Link pending
ea022011401ex32-2_unicycive.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
ea0220114-10q_unicycive_htm.xml Edgar Link completed
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
uncy-20240930.xsd Edgar Link pending
uncy-20240930_cal.xml Edgar Link unprocessable
uncy-20240930_def.xml Edgar Link unprocessable
uncy-20240930_lab.xml Edgar Link unprocessable
uncy-20240930_pre.xml Edgar Link unprocessable